

REC Ref No.	IRAS No.	Name of Trial	Target Number of Participants Available?	Recruitment Target	Target Date To Recruit Participants Available?	Date Agreed To Recruit Target Number of Participants	Total Number of Participants Recruited at The Agreed Target Date	Date Study Closed to Recruitment	Recruitment Total	Recruitment Closure Reason
18/NW/0107	236834	PHIL evaluation in the endovascular treatment of intracranial cerebral ArterioVenous Malformation	Number Agreed	6	Date Agreed	31/08/2019	0	26/10/2018	0	Withdrawn By Sponsor
18/LO/0666	242700	Extended Access of Momelotinib for Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF).	Number Agreed	2	Date Agreed	01/07/2020	2	22/10/2018	2	Recruitment Finished
18/LO/1063	236384	The efficacy and safety of initial triple versus initial dual oral combination therapy in patients with newly diagnosed pulmonary arterial hypertension: A multi-center, double-blind, placebo-controlled, Phase 3b study-Actellion - AC-065A308	Range Agreed	3	Date Agreed	29/12/2018	2	29/12/2018	2	Recruitment Finished
17/SC/0394	229032	An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Previously Treated with Ruxolitinib	Number Agreed	3	Date Agreed	31/12/2018	4	12/12/2018	4	Recruitment Finished
17/EM/0154	222912	A Multi-centre, Double-blind, Randomised, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety and Tolerability of 28-Day Oral Treatment with PXT002331 (foliglurax) in Reducing Motor Complications of Levodopa Therapy in Sub	Number Agreed	4	Date Agreed	01/12/2018	5	01/12/2018	5	Recruitment Finished
17/LO/0863	228208	EU- Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy use in secondary and primary care - Da Vinci	Number Agreed	45	Date Agreed	30/04/2018	43	20/11/2018	43	Recruitment Finished
17/SC/0122	224090	AR101 Trial in Europe Measuring Oral Immunotherapy Success in Peanut Allergic Children	Number Agreed	12	Date Agreed	01/12/2017	12	01/12/2018	15	Recruitment Finished
17/SC/0291	226509	The DEFINE PCI study: Physiologic assessment of coronary stenosis following PCI.	Number Agreed	20	Date Agreed	31/03/2019	7	28/01/2019	7	Withdrawn By Sponsor
17/EE/0079	220827	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168(Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Treated Concomitantly with Rituximab or Cyclophosph	Number Agreed	1	Date Agreed	31/12/2018	1	31/12/2018	1	Recruitment Finished
16/NE/0067	199159	A Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of Deferiprone Delayed Release Tablets in Patients with Parkinson's Disease.	Number Agreed	4	Date Agreed	31/12/2017	6	03/12/2018	6	Recruitment Finished
16/EE/0357	206501	Efficacy and safety of opicapone in clinical practice in Parkinson's Disease patients with wearing-off motor fluctuations	Number Agreed	4	Date Agreed	30/11/2017	8	18/10/2018	8	Recruitment Finished
16/LO/1244	200385	A Phase 3 Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM-CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy	Number Agreed	3	Date Agreed	31/03/2019	3	12/11/2018	4	Recruitment Finished

16/LO/0443	197312	A multicentre, open-label, multiple-dose study to evaluate the safety, tolerability and efficacy of UCB7665 in subjects with primary immune thrombocytopenia (ITP)	Number Agreed	1	Date Agreed	30/12/2018	1	30/12/2018	1	Recruitment Finished
16/YH/0083	192397	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With nab Paclitaxel Plus Gemcitabine Compared With Placebo Plus nab Paclitaxel and Gemcitabine in Subject	Number Agreed	10	Date Agreed	30/04/2019	11	26/11/2018	11	Recruitment Finished
15/WM/0453	172946	A Open Label, Randomised, Pre-surgical, Pharmacodynamics Study to Compare the Biological Effects of AZD9496 versus Fulvestrant in Postmenopausal Women with estrogen receptor positive HER-2 negative Primary Breast Cancer	Number Agreed	5	Date Agreed	30/11/2018	2	30/11/2018	2	Recruitment Finished
15/SC/0616	188838	An exploratory, randomised, double-blind, placebo-controlled study of the effects of dupilumab on airway inflammation of adults with persistent asthma	Number Agreed	3	Date Agreed	27/07/2017	1	17/10/2018	1	Recruitment Finished
16/EM/0259	165592	A prospective, multicentre, open-label, randomized, active-controlled, 3 parallel groups, phase 2 study to compare the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid), versus masitinib alone,	Number Agreed	3	Date Agreed	06/11/2018	3	06/11/2018	3	Recruitment Finished
15/NW/0592	185435	A randomised, double-blind, double-dummy, placebo-controlled, parallel-group multi-centre clinical proof-of-principle trial in adult subjects with newly diagnosed type 1 diabetes mellitus investigating the effect of NNC0114-0006 and liraglutide on pr	Number Agreed	1	Date Agreed	27/11/2018	1	27/11/2018	1	Recruitment Finished
14/YH/1153	159477	An Open-Label, Extension Study of the Effects of Leuco-methylthionium bis (hydromethanesulfonate) in Subjects with Alzheimer?s Disease or Behavioral Variant Frontotemporal Dementia	Number Agreed	10	Date Agreed	10/10/2018	14	10/10/2018	14	Recruitment Finished
15/LO/1538	188226	A study to evaluate the effectiveness and safety of Exablate transcranial MRgFUS thalamotomy treatment of medication refractory essential tremor subjects	Number Agreed	10	Date Agreed	13/02/2019	17	13/02/2019	17	Recruitment Finished
16/EE/0386	208339	A Multicentre, Randomised, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5- Fluorouracil (5-FU)/Folinic Acid (FA) /Irinotecan (FOLFIRI)/Cetuximab with a Safety Lead-in of E	Number Agreed	5	Date Agreed	31/01/2019	5	31/01/2019	5	Recruitment Finished
13/LO/1227	124209	A Multicenter, Randomized, DoubleBlind, PlaceboControlled, Phase III Study of ARN509 in Men with NonMetastatic (M0) CastrationResistant Prostate Cancer	Number Agreed	5	Date Agreed	30/11/2018	2	30/11/2018	2	Recruitment Finished
13/LO/1081	132715	A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer	Number Agreed	1	Date Agreed	31/12/2018	0	31/12/2018	0	Recruitment Finished
15/SC/0003	154916	An Open-Label, Multicenter, Phase 1/2 Study of E7438 (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B cell Lymphomas.	Number Agreed	3	Not Available / Not Agreed			10/06/2019	7	Recruitment Finished

15/SC/0359	173940	M13-694: A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fall	Number Agreed	6	Date Agreed	01/01/2019	4	01/01/2019	4	Recruitment Finished
15/WM/0392	180166	Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer	Number Agreed	3	Date Agreed	01/03/2019	0	30/06/2019	0	Recruitment Finished
15/LO/1192	183464	A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses.	Number Agreed	2	Date Agreed	31/10/2019	4	26/04/2019	4	Recruitment Finished
16/LO/0581	194313	Phase 2, Randomized Study of MLN0128 (a Dual TORC1/2 Inhibitor), MLN0128+MLN1117 (a PI3Ka Inhibitor), Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MLN0128 in women With Advanced, Recurrent, or Persistent Endometrial Cancer	Number Agreed	4	Date Agreed	31/10/2018	5	17/10/2018	5	Recruitment Finished
17/LO/0100	200545	A Multicenter, Randomized, Open-label Clinical Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens	Number Agreed	1	Date Agreed	28/02/2019	0	22/02/2019	0	Recruitment Finished
16/SW/0120	201715	Study of the optimum duration of acoustic pulse thrombolysis procedure in the treatment of acute submassive pulmonary embolism	Number Agreed	8	Date Agreed	19/03/2020	0	01/05/2019	0	Withdrawn By Sponsor
17/SC/0201	209172	Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study.	Range Agreed	3	Date Agreed	01/09/2023	2	10/06/2019	2	Recruitment Finished
16/SC/0600	209261	Combined Phase 2b/3, Double blind, Randomised, Placebo-Controlled Studies Evaluating the Efficacy and safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease	Number Agreed	2	Date Agreed	31/03/2019	1	31/03/2019	1	Recruitment Finished
16/EM/0382	210424	A multicenter, randomized, double-blind, active-controlled study to evaluate the effects of LCZ696 compared to valsartan on cognitive function in patients with chronic heart failure and preserved ejection fraction.	Number Agreed	2	Date Agreed	29/03/2019	2	15/02/2019	2	Recruitment Finished
16/SC/0653	215441	A Phase 3, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Niraparib Maintenance Treatment in Patients with HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy	Number Agreed	4	Date Agreed	20/07/2018	3	17/04/2019	3	Recruitment Finished
17/LO/0339	219974	MK-3475 (Pembrolizumab) Protocol 412: Study of Pembrolizumab given concomitantly with Chemoradiation and as maintenance therapy versus Chemoradiation alone in subjects with locally advanced head and neck squamous cell carcinoma KEYNOTE 412	Number Agreed	4	Date Agreed	31/03/2019	7	31/03/2019	7	Recruitment Finished
17/NE/0174	224141	A PERFORMANCE EVALUATION STUDY OF ARQUER'S MCM5 ELISA TEST TO AID IN THE MONITORING OF BLADDER CANCER RECURRENCE	Number Agreed	10	Date Agreed	30/06/2019	23	30/06/2019	23	Recruitment Finished
17/NW/0351	224954	A phase II single arm clinical trial of a Tailored ImmunoTherapy Approach with Nivolumab in subjects with metastatic or advanced Renal Cell Carcinoma	Number Agreed	2	Date Agreed	01/10/2018	3	01/10/2018	3	Recruitment Finished

17/LO/1040	226283	p53 Suppressor Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Phase II Study of Systemic Pegylated Liposomal Doxorubicin Chemotherapy With APR-246	Number Agreed	2	Date Agreed	31/10/2018	2	31/10/2018	2	Recruitment Finished
17/SC/0408	228262	A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination with Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease.	Number Agreed	2	Date Agreed	03/04/2019	3	03/04/2019	3	Recruitment Finished
17/LO/1247	228533	RANDOMIZED, OPEN LABEL, MULTICENTRE, PHASE 3 STUDY OF ROVALPITUZUMAB TESIRINE COMPARED WITH TOPOTECAN FOR SUBJECTS WITH ADVANCED OR METASTIC DLL3 SMALL CELL LUNG CANCER (SCLC) WHO HAVE FIRST DISEASE PROGRESSION DURING OR FOLLOWING FRONT LINE PLATINUM	Number Agreed	2	Date Agreed	29/03/2019	2	29/03/2019	2	Recruitment Finished
17/LO/1320	229845	Single-arm, phase II study of Luspatercept (ACE-536) in anemic patients with MPN-associated myelofibrosis.	Number Agreed	3	Date Agreed	28/02/2019	2	26/04/2019	2	Recruitment Finished
18/LO/0719	235423	A Phase 2, Proof-of-Concept, Randomized, Double-Blinded, Placebo-Controlled Study of ACH-0144471 Treatment for 6 Months in Patients with C3 Glomerulopathy (C3G)	Number Agreed	5	Date Agreed	30/04/2019	1	30/04/2019	1	Recruitment Finished
18/WA/0385	254760	NOVA	Number Agreed	5	Date Agreed	30/09/2019	0	30/09/2019	0	Recruitment Finished
18/EM/0311	254008	A new treatment for rhinovirus-induced symptoms in smokers	Number Agreed	20	Date Agreed	01/08/2019	10	01/08/2019	10	Recruitment Finished
18/NW/0765	250220	Validating a Device for the Detection of Bacteria and Leukocytes in Peritoneal Effluent from Patients with Suspected Peritonitis	Number Agreed	0	Date Agreed	31/08/2019	0	31/08/2019	0	Recruitment Finished
17/EM/0412	234907	CLNP023X2203 - Safety and efficacy study of LNP023 in IgA Nephropathy	Number Agreed	1	Date Agreed	30/04/2019	0	30/04/2019	0	Recruitment Finished
18/EE/0005	232671	Effect on HRCT Endpoints to Glucocorticoid in Pulmonary Sarcoidosis	Number Agreed	1	Date Agreed	31/05/2019	1	31/05/2019	1	Recruitment Finished
17/WM/0146	220303	Efficacy and Safety of E2609 in Subjects with Alzheimer's Disease E2609-G000-301	Number Agreed	4	Date Agreed	01/02/2019	4	01/02/2019	4	Recruitment Finished
17/LO/0849	222165	GS-US-384-1944: Safety & Efficacy of SEL in Patients w/ Cirrhosis due to NASH; (STELLAR-4)	Number Agreed	2	Date Agreed	31/12/2018	2	31/12/2018	2	Recruitment Finished
17/LO/0848	222163	GS-US-384-1943: Safety & Efficacy of SEL in Patients w/ NASH & Bridging Fibrosis (STELLAR-3)	Number Agreed	2	Date Agreed	31/12/2018	3	31/12/2018	3	Recruitment Finished
16/SC/0390	190073	Efficacy and safety of ofatumumab vs teriflunomide in RMS (OMB2301)	Number Agreed	4	Date Agreed	01/05/2019	0	01/05/2019	0	Recruitment Finished
18/LO/0359	242661	GBT440-032: Phase 3 study in participants with sickle cell disease (HOPE Kids 2)	Number Agreed	2	Date Agreed	31/07/2019	0	31/07/2019	0	Recruitment Finished
17/LO/0304	222475	IXA-CSP-001 Litoxetine v Placebo in Urinary Incontinence	Number Agreed	10	Date Agreed	31/10/2018	0	31/10/2018	0	Withdrawn By Sponsor
17/LO/0052	212454	OPEN	Number Agreed	10	Date Agreed	01/11/2018	9	01/11/2018	9	Recruitment Finished
17/NE/0300	225917	UM203	Number Agreed	18	Date Agreed	30/08/2019	17	30/08/2019	17	Recruitment Finished
16/LO/0422	198606	SRA737-02	Number Agreed	0	Date Agreed	31/03/2019	0	31/03/2019	0	Recruitment Finished

18/YH/0136	214921	Biovotec- DermaRep Device	Number Agreed	5	Date Agreed	30/09/2019	4	30/09/2019	4	Recruitment Finished
18/LO/0430	241907	PRN1008 – an Oral BTK Inhibitor in Patients with Relapsed ITP	Number Agreed	1	Date Agreed	31/08/2019	1	31/08/2019	1	Recruitment Finished
17/EM/0406	235483	PRTX-100 in ITP (PRTX-100-202)	Number Agreed	1	Date Agreed	30/07/2019	0	30/07/2019	0	Recruitment Finished
18/LO/1461	245412	A Phase 2 Study of Sotatercept for the Treatment of PAH-PULSAR A011-09	Number Agreed	2	Date Agreed	30/09/2019	1	07/06/2019	1	Recruitment Finished
18/NE/0136	240494	CA2099DX_Ph3 Double Blind Liver Cancer Study using Nivolumab	Number Agreed	1	Date Agreed	24/09/2019	0	24/09/2019	0	Recruitment Finished
17/SC/0639	236312	BMN - 270-302	Number Agreed	1	Date Agreed	30/09/2019	0	30/09/2019	0	Recruitment Finished
17/LO/1695	234684	BMN 270-301: Gene Therapy Study in Severe Haemophilia A Patients	Number Agreed	1	Date Agreed	26/09/2019	3	26/09/2019	3	Recruitment Finished
17/LO/1429	223671	CLR_15_03	Number Agreed	2	Date Agreed	31/12/2018	2	31/12/2018	2	Recruitment Finished
17/EM/0338	229242	CABL001A2301	Number Agreed	1	Date Agreed	22/11/2018	5	22/11/2018	5	Recruitment Finished
17/EE/0026	220207	A Clinical Study of the ACRYSOFF® IQ EDF IOL	Number Agreed	10	Date Agreed	01/10/2018	11	01/10/2018	11	Recruitment Finished
17/YH/0311	229294	CARRICK001 - CT7001 Carrick Therapeutics study	Number Agreed	6	Date Agreed	31/10/2018	14	31/10/2018	14	Recruitment Finished
17/NE/0151	223815	ASTRAL-2 SGI-110-06	Number Agreed	2	Date Agreed	31/12/2018	0	31/12/2018	0	Withdrawn By Sponsor
17/EE/0264	228153	POSEIDON	Number Agreed	6	Date Agreed	08/11/2018	3	08/11/2018	3	Recruitment Finished
17/LO/0525	221541	MERCURY 3	Number Agreed	1	Date Agreed	01/09/2019	1	01/09/2019	1	Recruitment Finished
17/ES/0051	223060	PRO-105	Number Agreed	3	Date Agreed	30/09/2019	5	30/09/2019	5	Recruitment Finished
16/WM/0448	212745	SHP620-303	Number Agreed	2	Date Agreed	19/05/2019	0	19/05/2019	0	Recruitment Finished
16/SC/0143	200373	Keynote 057	Number Agreed	3	Date Agreed	01/12/2018	0	01/12/2018	0	Recruitment Finished
17/NW/0254	225698	KEYNOTE-564 - CANC 32708	Number Agreed	6	Date Agreed	15/10/2018	11	15/10/2018	11	Recruitment Finished
17/SC/0253	226685	MonarchE - 13Y-MC-JPCF	Number Agreed	5	Date Agreed	28/06/2019	11	28/06/2019	11	Recruitment Finished
17/WS/0120	225090	TRACE	Number Agreed	2	Date Agreed	01/09/2019	8	01/09/2019	8	Recruitment Finished
17/NE/0036	208636	SIR-Spheres for the treatment of cholangiocarcinoma - CANC 31007- SIRCCA	Number Agreed	6	Date Agreed	31/01/2019	6	31/01/2019	6	Recruitment Finished
16/EM/0465	214926	INCYTE, Efficacy and Safety of INCB054828 in Urothelial Cancer	Number Agreed	1	Date Agreed	30/09/2019	2	30/09/2019	2	Recruitment Finished
17/LO/0082	217324	PuraStat-002-VASC	Number Agreed	3	Date Agreed	30/09/2019	10	30/09/2019	10	Recruitment Finished
14/WA/1118	159836	Pathos	Number Agreed	3	Date Agreed	20/02/2019	7	20/02/2019	7	Recruitment Finished

15/YH/0434	185622	GS-US-313-1580	Number Agreed	2	Date Agreed	01/06/2019	0	01/06/2019	0	Withdrawn By Host
15/SC/0409	183061	SEQUOIA (DARPIN) - OPHT 4170 (AMD)	Number Agreed	10	Date Agreed	03/06/2019	0	03/06/2019	0	Recruitment Finished
14/EM/1102	160472	EBBINGHAUS	Number Agreed	7	Date Agreed	30/12/2018	0	30/12/2018	0	Recruitment Finished